Hematology-Oncology and Stem Cell Transplantation Research Center

Atreca Appoints Philippe Bishop, MD as Chief Medical Officer

Retrieved on: 
星期一, 一月 9, 2023
National Cancer Institute, Sanofi, University, Gilead Sciences, SCB-2019, National Institutes of Health, Regulation of tobacco by the U.S. Food and Drug Administration, Trial of the century, MD, University of Washington School of Medicine, Vaccine, Internal medicine, Food, Therapy, Genentech, Hematology-Oncology and Stem Cell Transplantation Research Center, SAN, Antibody, CMO, Hematology, Employment, Pharmaceutical industry

SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Philippe Bishop, MD, as Chief Medical Officer (CMO), effective immediately.

Key Points: 
  • SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Philippe Bishop, MD, as Chief Medical Officer (CMO), effective immediately.
  • Bishop is a tremendous addition to the Atreca team at an important time in the clinical development of ATRC-101.
  • As an accomplished executive and medical oncologist with extensive experience in cancer drug development, his leadership and expertise will be invaluable as we continue to advance ATRC-101, as well as our earlier stage programs,” said John Orwin, Chief Executive Officer of Atreca.
  • This award was granted as an inducement material to Dr. Bishop entering into employment with Atreca in accordance with Nasdaq Listing Rule 5635(c)(4).

Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

Retrieved on: 
星期二, 一月 3, 2023
GlaxoSmithKline, Acceleration, University of California, San Francisco, Medical Center, Internal medicine, Hematology-Oncology and Stem Cell Transplantation Research Center, Michael Reese Hospital, Division, R, Amgen, Patient, Development, D, Research and development, University, UCLA, Senior, Oncology, Fine chemical, Medical device, Research, Hematology

as President, Head of Global Oncology Research and Development, effective December 30, 2022.

Key Points: 
  • as President, Head of Global Oncology Research and Development, effective December 30, 2022.
  • Dr. Amado brings to Zai Lab deep expertise in the field of oncology and significant global biopharmaceutical R&D leadership.
  • “We are pleased to welcome Rafael to our executive leadership team,” said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab.
  • He will be responsible for leading and overseeing the Company’s global oncology research and development activities.

Elligo Health Research® Names Dawn Sauro as New Chief Operating Officer

Retrieved on: 
星期四, 一月 5, 2023
Health, Practice Management, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Research strategies of election campaign communication research, Drug development, Research, Health minister, Multimedia, Human Development Innovation Fund, Minnie Pearl, Cros, Patient, Hematology-Oncology and Stem Cell Transplantation Research Center, Hematology, Senior, Pharmaceutical industry

Elligo Health Research , the largest healthcare-enabling research organization, today announced that Dawn Sauro has been named as Elligo’s Chief Operating Officer (COO) to help further the company’s growth, efficiency, and mission of optimizing the intersection of healthcare and research through direct access to patients, new technology, and custom research practice management solutions.

Key Points: 
  • Elligo Health Research , the largest healthcare-enabling research organization, today announced that Dawn Sauro has been named as Elligo’s Chief Operating Officer (COO) to help further the company’s growth, efficiency, and mission of optimizing the intersection of healthcare and research through direct access to patients, new technology, and custom research practice management solutions.
  • View the full release here: https://www.businesswire.com/news/home/20230105005290/en/
    Dawn Sauro is Elligo Health Research’s new Chief Operating Officer.
  • Prior to joining Elligo, Sauro was Chief Development Officer at Clinipace Clinical Research (now Caidya) where she grew the organization to be a trusted partner for sponsors across a variety of therapeutic areas.
  • Prior roles also included President, Development Innovations at Sarah Cannon and Senior Vice President and General Manager, Hematology/Oncology at inVentiv Health (now Syneos).

IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100

Retrieved on: 
星期一, 十二月 12, 2022
HSCT, Lymphatic system, Blood, Security (finance), Fatigue, Webcast, Principal investigator, Exposition, ASH, Infrared spectroscopy correlation table, Vomiting, CMV, AML, Hematopoietic stem cell transplantation, Cohort, COVID-19, Glioblastoma, Hematology-Oncology and Stem Cell Transplantation Research Center, Graft-versus-host disease, University, Clinical trial, Safety, CRS, Constipation, Society, KUCC, IPSC, Deltex Medical Group, Disease, Immune system, Medical director, Patient, Cytomegalovirus, Leukemia, Cytokine release syndrome, AES, Poster, Magnesium, CR, Acute myeloid leukemia, Risk, Event, Pharmaceutical industry, Medical imaging

As of December 9, 2022, four patients have received the first dose level (DL) of INB-100 (1 x 106 cells/kg) and remain on study and in remission.

Key Points: 
  • As of December 9, 2022, four patients have received the first dose level (DL) of INB-100 (1 x 106 cells/kg) and remain on study and in remission.
  • Steroid-responsive cutaneous acute Grade 1/2 graft-versus-host disease (GvHD) has been observed in all patients, with one patient experiencing Grade 2 intestinal GvHD.
  • Two patients have been enrolled and dosed in Cohort 2, evaluating INB-100 at a dose level of 3 x 106 cells/kg.
  • IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements.

Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Retrieved on: 
星期六, 十二月 10, 2022
Lymphoma, Samsung Medical Center, Cell, University, FDG-PET, NK, CST, Clinical trial, Terrorism, Neoplasm, Hodgkin lymphoma, Macrophage, Safety, Peripheral T-cell lymphoma not otherwise specified, Probability, Cancer, DOR, Biotechnology, Pharmacokinetics, OS, CD30, Affimer, REDIRECT, Dor, EST, ORR, Growth, ID, MD Anderson Cancer Center, IRC, COVID-19, Patient, PFS, Hematology-Oncology and Stem Cell Transplantation Research Center, Pharmaceutical industry, Online shopping, Vaccine, PTCL

The safety profile of AFM13 was well managed and consistent with previously reported data of prior and ongoing clinical studies with AFM13.

Key Points: 
  • The safety profile of AFM13 was well managed and consistent with previously reported data of prior and ongoing clinical studies with AFM13.
  • “Our parallel study investigating AFM13 in combination with allogeneic NK cells shows that this combination can materially improve clinical outcomes for patients with CD30-postive lymphomas.
  • Secondary and exploratory outcome measures included DoR, PFS, OS, the safety of AFM13 as well as pharmacokinetics and immunogenicity of AFM13.
  • AFM13 is Affimed’s most advanced ICE® clinical program and is currently being evaluated as monotherapy in a registration-directed trial in patients with relapsed/refractory peripheral T-cell lymphoma (REDIRECT).

CytoSite Bio Presents First-in-Human Data at Radiological Society of North American Annual Meeting

Retrieved on: 
星期一, 十一月 28, 2022
Oncology, Health, Clinical Trials, Research, Radiology, Science, Doctor of Philosophy, Massachusetts General Hospital, Immune system, PET, Hematology-Oncology and Stem Cell Transplantation Research Center, Drug combination, NSCLC, Hospital, GZMB, RSNA, Large-cell lung carcinoma, Physician, Melanoma, Patient, ICI, Hematology, Neoplasm, Oncology, Pembrolizumab, Radiological Society of North America, Annual general meeting, MD, NK, Cancer, Granzyme, Immunotherapy, Associate, Safety, Principal, Medical imaging

CytoSite Bio , a company developing precision imaging products that determine patient response to immuno-oncology therapy today shared new data at the Radiological Society of North American (RSNA) Annual Meeting in Chicago, IL.

Key Points: 
  • CytoSite Bio , a company developing precision imaging products that determine patient response to immuno-oncology therapy today shared new data at the Radiological Society of North American (RSNA) Annual Meeting in Chicago, IL.
  • These data come from a Phase I trial assessing the safety and feasibility of GzmB PET imaging in subjects with melanoma and non-small cell lung cancer (NSCLC) receiving KEYTRUDA (pembrolizumab).
  • I am pleased that these early, promising data are showing how that option could become a reality.
  • CytoSite Bio is developing precision imaging products that determine patient response to immuno-oncology therapy very early in the treatment cycle.

The Oncology Institute Expands into Miami-Dade County, Hires National Oncology Leader Dr. Roberto Ochoa

Retrieved on: 
星期二, 十一月 22, 2022
STE, COVID-19, Palliative care, National Directorate for Personal Data Protection, Sunset Drive, American Oncology Institute, The Learning Company (formerly SoftKey), Risk, Partnership, Physician, Patient, Hematology-Oncology and Stem Cell Transplantation Research Center, Oncology, Chenming Hu, Acquisition, Probability, Hospital, Medical imaging

Dr. Roberto Ochoa, former National Director, Hematology/Oncology and Palliative Care at ChenMed, will serve as the newly appointed Senior Medical Director for the state of Florida.

Key Points: 
  • Dr. Roberto Ochoa, former National Director, Hematology/Oncology and Palliative Care at ChenMed, will serve as the newly appointed Senior Medical Director for the state of Florida.
  • Dr. Ochoa, who will also be seeing patients at the South Miami clinic, shared, I am enthusiastic to begin working for the leader in value-based oncology as it expands throughout the region.
  • Their value-based model is a perfect fit to my practice, and I know my patients will benefit from this new relationship.
  • The Oncology Institute anticipates that subsequent events and developments will cause The Oncology Institutes assessments to change.

Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update

Retrieved on: 
星期一, 十一月 14, 2022
Research, Other Health, General Health, Pharmaceutical, Oncology, Biometrics, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, FDA, Health, Investment, Overalls, Society for Immunotherapy of Cancer, CBC, CAR, Prescription Drug User Fee Act, Hematological Cancer Research Investment and Education Act, NK, Lymphatic system, Cell, ASH, Cancer, Highbridge Capital Management, Letter, CRISPR, Safety, Society, PDUFA, NAM, Center for International Blood and Marrow Transplant Research, The Year's Best Science Fiction: Tenth Annual Collection, Growth, Hematology-Oncology and Stem Cell Transplantation Research Center, Immunotherapy, SOHO, SITC, Database, Patient, Pharmaceutical industry

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended September 30, 2022.

Key Points: 
  • Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended September 30, 2022.
  • Net loss for the third quarter of 2022 was $17.8 million, compared to a net loss of $23.2 million in the third quarter of 2021.
  • As of September 30, 2022, Gamida Cell had total cash, cash equivalents and investments of $61.3 million.
  • Strengthened financial position: In September 2022, Gamida Cell executed an underwritten public offering raising approximately $20 million, before deducting underwriting discounts, commissions and offering expenses.

CTI BioPharma Reports Third Quarter 2022 Financial Results

Retrieved on: 
星期一, 十一月 7, 2022
Janus, Society, Ruxolitinib, Nasdaq, Pacritinib, Thrombocytopenia, Platelet, Data analysis, Annual general meeting, Operating cost, Bleeding, ID, Investment, Myeloproliferative neoplasm, ASH, Hematology-Oncology and Stem Cell Transplantation Research Center, Primary myelofibrosis, Vera, CTI, Growth, Galena Biopharma, FLT3, ALK2, Webcast, JAK2, Anemia, CTIC, Patient, Mastocytosis, Telephone, JAK1, BID, Haematopoiesis, SOHO, Safety, Syndrome, Cytokine, FDA, Pharmaceutical industry, ACVR1

SEATTLE, Nov. 7, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter ended September 30, 2022.

Key Points: 
  • ET
    SEATTLE, Nov. 7, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter ended September 30, 2022.
  • "In the third quarter, CTI continued to make strong progress with the U.S. commercial launch of VONJO, delivering net revenue of $18.2 million, a 48% increase in sales compared to the second quarter.
  • CTI will host a conference call and webcast to review its third quarter 2022 financial results and provide an update on business activities today, November 7, 2022, at 4:30 p.m.
  • "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions.

ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results

Retrieved on: 
星期五, 十一月 4, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Society, Bevacizumab, Ovarian cancer, FDA, PIN, Zenith Contract Services, Research, ImmunoGen, U.S. Securities and Exchange Commission, Clinical trial, Lilly, Oncology, Capital expenditure, National Comprehensive Cancer Network, Society of Gynecologic Oncology, Program, ESGO, Venetoclax, Company, Congress, BLA, Carboplatin, ASH, Gynecologic Oncology (journal), BPDCN, Journal of the National Comprehensive Cancer Network, PDUFA, Hematology-Oncology and Stem Cell Transplantation Research Center, Security (finance), IMGN, Control, Patient, Cancer, ADC, Maintenance, Azacitidine, ESMO, European Society of Gynaecological Oncology, COVID-19, Annual general meeting, Novartis, SOHO, NCCN, SGO, Acute myeloid leukemia, Standard of care, Risk, AML, György Enyedi (geographer), Vaccine, Pharmaceutical industry, Medical imaging, Platinum, Cryptocurrency

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2022.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2022.
  • With an intense focus on execution, we are well positioned to transform ImmunoGen into a fully-integrated oncology company this year.
  • Total revenues were $15.4 million for the quarter ended September 30, 2022 compared to $9.2 million for the quarter ended September 30, 2021.
  • Operating expenses for the quarter ended September 30, 2022 were $92.8 million, compared with $43.4 million for the same quarter in 2021.